South Africa: Patients' Rights: The Achilles Heel Of The Patient System? An Indian Perspective For South Africa

Last Updated: 7 June 2012
Article by Neil Kirby

Currently there is litigation between a numbers of parties concerning the application of a patent in respect of a cancer medicine in South Africa. The parties concerned include Sanofi Aventis SA (Proprietary) Limited and Cipla Medpro (Proprietary) Limited ("Cipla"). The particular medicine concerned is a generic medicine currently being made available by Cipla and referred to as Cipla Docetaxel. The appellants, amongst them Sanofi Aventis SA (Proprietary) Limited, are endeavouring to obtain interim interdicts against the respondents preventing the respondents from making available and selling the medicine concerned in so far as the generic medicine infringes a patent held by the appellants under South African patent number 93/8936 and entitled "New Taxoid-Based Compositions.

The litigation is based primarily, if not exclusively, on the provisions of the Patents Act No. 57 of 1978. One of the aspects that has been raised within the context of the litigation, now before the Supreme Court of Appeal, is whether or not patients' rights have a role to play in determining whether or not patents should be protected. It is the issue of patients' rights that may bring into sharp focus the balancing act that a court will ultimately have to strike between the property rights contained in section 25 of the Constitution of the Republic of South Africa, 1996 ("the Constitution") and the right to access healthcare in section 27(1)(a) of the Constitution.

The current debate before the Supreme Court of Appeal follows debates in developing countries such as India and Brazil about the rights of patent holders of medicines, on the one hand, and the rights of generic manufacturers to sell medicines notwithstanding certain patent protections, on the other hand. The debates are premised on the rights of the Governments of developing countries to alter property regimes in order to facilitate, it is argued, the provision of medicine to and increase access to healthcare services for their populations.

The decisions of courts in other jurisdictions are also central to the issue of formulating the particular public interest arguments in the matter before the Supreme Court of Appeal, more particularly, the decision of Roche vs Cipla 159 (2009) DLT 243, MIPR 2009 (2) 1 ("the Indian decision"). The Indian decision is of great interest in relation to the stance that it intends to take on matters of access to cancer medicine for people living with HIV.

The Indian decision concerns the granting of an interdict in respect of the availability of a generic medicine in India pending the determination of a patent dispute. The Indian decision is a decision of the High Court of Delhi held at New Delhi and is an appeal decision. The Indian decision concerns a number of aspects concerning Indian patent law that are unique to this system of law based on the legislation applicable to patents in India. However, the Indian decision does deal with the issue of patients' rights in the context of the principles of "public interest.

The public interest is defined principally with reference to the harm that would ultimately be visited upon patients should a particular medicine become unavailable due to, in the Indian decision, a court granting an interdict. This harm is based on very particular evidence.

The evidence, in turn, is based on two primary premises: the first is how unique the medicine is in a particular market and the second is how successful the medicine is in treating a particular condition, which must ultimately be a medicine of a life-saving nature. The Indian decision summarises the decision of the first court before which the matter served in respect of the public interest as follows:–

"The Court cannot be unmindful of the general access to life-saving products and the possibility that such access would be denied if [an] injunction was granted. If the Court was of the opinion that the public interest in granting an injunction in favour of the plaintiff during the pendency of an infringement action is outweighed by the public interest of ensuring easy and affordable access to a life saving drug, the balance should tilt in favour of the latter. In the instance case irreparable injury would be caused to the public if the injunction was granted as they would be deprived of the defendant's product. Several unknown persons who are not parties to the suit and who would be deprived of the life saving drug would not be able to be restituted in monetary terms for the damage that would be caused to them if the injunction was granted." (See paragraph 24 at page 9 of the Indian decision).

What emerges from the Indian decision are the criteria to be used to address issues concerning public interest in the context of patients' rights. In this regard, the criteria need to be considered carefully in relation to how these criteria relate to the provisions of section 27(1)(a) of the Constitution. These criteria are the following: –

  • the medicine in question must be a lifesaving medicine and used for a medical condition that has serious medical and social implications, such as cancer or HIV;
  • the unavailability of the medicine, due to the granting of an interdict or similar court action, would cause such harm to patients so as to result in harm that could never be remedied in any manner by an alternative medicinal substance or treatment;
  • the cost at which the medicine is being made available to the public and whether or not, based on the economic realities of the population that uses the medicine, that medicine is affordable. This is an important aspect of the matter as this is the counter argument to the argument that was raised in the Indian decision that "if the rights of a patentee are not respected then it would be contrary to the public interest of encouraging further research. Further it would discourage the requirement of disclosure which inheres in patent regime thereby creating a situation where opportunity of further innovation based on fundamental research on an existing patent product/process would be lost or unduly deferred." (See paragraph 72 on page 21 of the Indian decision). The High Court of Delhi rejected this as a basis for granting the interdict or dealing with the issue of public interest on the basis that "[t]his court is unable to accept the submissions of the plaintiffs on this aspect. The amendment to the Patents Act 1970 in 2005 introduced Section 83(e) which states that among the general principles applicable to the working of patented inventions regard shall be had 'that patents granted do not in any way prohibit Central Government in taking measures to promote public health' and under Section 83(g) 'that patents are granted to make the benefit of the patented invention available at reasonably affordable prices to the public.' Under Section 84 among the grounds on which a person can seek a compulsory license on a patent is that 'the patented invention is not available to the public at reasonably affordable price.' The element of public interest is therefore not alien to the scheme of the Patents Act 1970." One aspect that one needs to consider in South Africa is that our patent legislation may not contain similar provisions to that of the Indian statute;
  • the demand for the medicine in a particular jurisdiction, which is a reference to epidemiological data;
  • the consequences of depriving members of the public of the benefit of the medicine (see paragraph 79 of page 23 of the Indian decision). This onus is borne by the patent holder and must take into account the following –

    "A life-saving drug is in an exceptional position. There are often cases where a number of drugs exist alongside each other and are in general all equally efficacious for a particular ailment of disease. If the evidence shows it to be the fact that there may well be cases where it would make little, if any, difference to the public, apart from satisfying personal preference, whether a particular drug was no longer available or not, then in such a case it may well be proper to grant an injunction. At the other end of the scale, however, there is the unique life-saving drug where, in my judgment, it is at least very doubtful if the court in its discretion ever ought to grant an injunction and I cannot at present think of any circumstances where it should." (See paragraph 79 at page 23of the Indian decision);

  • evidence concerning the views of patients in relation to whether they are peculiarly sensitive to and fearful of changes in medicine regimes (see paragraph 79 on page 23 of the Indian decision);
  • evidence of what would occur if greater availability of the particular medicine in a particular country were to occur i.e. the relief imposed upon the disease burden of a particular country;
  • the availability and success rate of the medicine in a population; and
  • based on all that is set out above, whether or not the granting of an interdict or the refusal to grant an interdict would cause a disservice to the public, which is a blending of the position under Indian law with a decision of the United States Supreme Court in the matter of eBay Incorporated v MercExchange 547 US 288 [2006].

The conclusion of the Indian decision, in respect of the public interest, was that "[t]he question of general public access in [India] to life-saving drugs assumes great significance and the adverse impact on such access which the grant of injunction in a case like the instant one is likely to have, would have to be accounted for. This Court finds no ground to differ with the reasoning or the conclusions arrived at by the learned Single Judge on this aspect." (See paragraph 85 on page 25 of the Indian decision).

A number of points are highlighted by this action and deserve consideration –

  • the issue of patients' rights may very well change the parameters of the debate about patents in South Africa as it has done in India;
  • whether or not one is comfortable that patients' rights should trump property rights and how one would balance the rights of patients with the rights of pharmaceutical manufacturers to protect their proprietary interests;
  • whether or not patients' rights always trumping proprietary interests is in the interests of future patients. Patient protection does facilitate and encourage further investment, research and development into new medicines, improvement in overall treatment regimens and facilitates access to aspects of treatment other than simply medicines such as medical devices, clinics, hospitals and similar centres of excellence.

The outcome of the matter before the Supreme Court of Appeal may very well influence political decision-making in so far as the power is already afforded to the Minister of Health ("the Minister"), in terms of section 15c(a) of the Medicines and Related Substances Act No. 101 of 1965, as amended, to take measures to ensure the supply of more affordable medicines. In terms of section 15c(a) the Minister is afforded the power to "prescribe conditions for the supply of more affordable medicines in certain circumstances so as to protect the health of the public, and in particular may ... may notwithstanding anything to the contrary contained in the Patents Act, 1978 (Act No. 57 of 1978), determine that the rights with regards to any medicine under a patent granted in the Republic shall not extend to acts in respect of such medicine which is being put into the market by the owner of the medicine, or with his or her consent." In so far as such a remedy is already available within the confines of South African law, it may be argued that the necessity for the Supreme Court of Appeal to deal with issues concerning patent rights, within the context of medicines available within the Republic, is unnecessary as with proper motivation, the Minister may be in a position to deal more appropriately with proprietary rights in the interests of the health of the public.

What does remain evident is that the issue of patients' rights is securely on the healthcare agenda of developing countries. The potential clash in South Africa between patients' rights and property rights is now inevitable within a context of the Constitution and the manner in which that document, as the supreme law of the Republic, endeavours to balance the rights of property holders and cancer patients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.